reports
Ageas and BNP Paribas: Transparency notification
Ageas and BNP Paribas: Transparency notification Ageas and BNP Paribas: Transparency notification In accordance with the rules on financial transparency*, BNP Paribas has notified Ageas on 22 November 2024 that, on 21 November 2024, the interest of its subsidiary BNP Paribas Cardif S.A. has exceeded the legal threshold of 10% of the shares issued by Ageas. BNP Paribas current shareholding stands at 11.86%. Reason for the notificationAcquisition or disposal of voting securities or voting rights Notification byA parent undertaking or a controlling person Persons subject to the notificatio...
Ageas et BNP Paribas: Notification de transparence
Ageas et BNP Paribas: Notification de transparence Ageas et BNP Paribas: Notification de transparence Conformément aux règles de transparence financière*, BNP Paribas introduit le 22 novembre 2024 une notification annonçant que, le 21 novembre 2024, la participation de sa filiale BNP Paribas Cardif S.A. a franchi, à la hausse, le seuil légal de 10% des actions émises par Ageas. La participation de BNP Paribas atteint ainsi 11,86%. Motif de la notificationAcquisition ou cession de titres conférant le droit de vote ou de droits de vote Notification parUne entreprise mère ou une personne d...
- Guy Sips
- Jacob Mekhael
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
Onward Medical 3Q24 update retains FDA approval timelines & highlights...
Onward reported its 3Q24 business update with no major surprises, while we note that the company reiterated the timeline for the key milestone of obtaining FDA clearance to launch its ARC-EX System in the US in 4Q24. Onward's cash runway was recently extended to around 2H26 (KBCSe) through a € 50m equity raise with cornerstone investor Ottobock, a global leader in prosthetics, orthotics and exoskeletons. All in all solid progress in the past few months. We take into account a small timeline shif...
ONWARD Medical Provides Q3 2024 Update and Year-to-Date Highlights
ONWARD Medical Provides Q3 2024 Update and Year-to-Date Highlights Raised EUR 50 million in new capital with cornerstone investment from Ottobock, now the Company’s top investor Signed exclusive license with CEA to develop and commercialize WIMAGINE Brain-Computer Interface (BCI) as part of the Company’s investigational ARC-BCI System Rob ten Hoedt, former Medtronic President and Executive Committee member, joined Board of Directors as incoming Chairman EINDHOVEN, the Netherlands, Nov. 26, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical tech...
argenx to Present at Upcoming Investor Conferences
argenx to Present at Upcoming Investor Conferences November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December. Citi’s 2024 Global Healthcare Conference. Fireside chat on Tuesday, December 3 at 1:45 p.m. ET in Miami, FL. 7th Annual Evercore I&I HealthCONx Conference. Fireside chat on Wednesday, December 4 at 1:45 p.m. ET in Coral Ga...
- Quirijn Mulder
Fugro/Outlook for 2025 strong/BUY
With 3Q24 revenues lower than estimated, the market turned quite negative on Fugro's outlook and the share price came under significant pressure. Although uncertainty has increased on the short-term outlook, including the possible impact of the Trump presidency, we believe the long term view has not changed. Renewables continue to grow whereas FID in oil and gas might be postponed but not cancelled. In our view, FY27 guidance of €3.0-3.5bn and 11-15% EBITA margin target are not under pressure. A...
Ageas reports on the progress of share buy-back programme
Ageas reports on the progress of share buy-back programme Ageas reports on the progress of share buy-back programme Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 52,761 Ageas shares in the period from 18-11-2024 until 22-11-2024. DateNumber ofSharesTotal amount(EUR)Average price(EUR)Lowest price(EUR)Highest price(EUR)18-11-20245,178251,96048.6648.5248.8219-11-20249,691466,81948.1747.8648.9020-11-20248,970435,89948.6048.4648.8021-11-202419,250931,77148.4048.1448.5222-11-20249,672469,64248.5648.3048.76Total52,7612,556,09...
Ageas rapporteert over de inkoop van eigen aandelen
Ageas rapporteert over de inkoop van eigen aandelen Ageas rapporteert over de inkoop van eigen aandelen Naar aanleiding van het aandelen-inkoopprogramma dat op 28 augustus 2024 aangekondigd werd, maakt Ageas bekend dat er 52.761 eigen aandelen ingekocht werden tussen 18-11-2024 en 22-11-2024. DatumAantalaandelenTotaal Bedrag(EUR)Gemiddelde koers(EUR)Laagste koers(EUR)Hoogste koers(EUR)18-11-20245.178251.96048,6648,5248,8219-11-20249.691466.81948,1747,8648,9020-11-20248.970435.89948,6048,4648,8021-11-202419.250931.77148,4048,1448,5222-11-20249.672469.64248,5648,3048,76Totaal52.7612.556.0904...
AB InBev Becomes Official Beer Partner of FIFA Club World Cup 2025™
NEW YORK--(BUSINESS WIRE)-- AB InBev (Euronext: ABI) (MEXBOL: ANB) (JSE: ANH) (NYSE: BUD), the world’s leading brewer, has extended its nearly 40-year partnership with FIFA to include the FIFA Club World Cup 2025™ taking place in the United States from June 15th to July 13th. AB InBev is also a sponsor of FIFA World Cup 2026™, which will be jointly hosted by 16 cities across Canada, Mexico and the United States. This press release features multimedia. View the full release here: AB InBev: Official Beer Partner of FIFA Club World Cup (Graphic: Business Wire) The expanded partnership reinforces...
Agfa-Gevaert NV: 1 director
A director at Agfa-Gevaert NV bought 80,000 shares at 0.681EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
RHM RHEINMETALL AG
BLND BRITISH LAND COMPANY PLC
GRF GRIFOLS S.A. CLASS A
ELE ENDESA S.A.
ISP INTESA SANPAOLO S.P.A.
TLX TALANX AG
UCG UNICREDIT S.P.A.
CABK CAIXABANK SA
GRF.P GRIFOLS S.A. PREF CLASS B
ARGX ARGEN-X SE
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
SGSN SGS SA
- Damien Choplain
- Martial Descoutures
Argenx : Efgartigimod enters phase III in myositis
>Positive phase II results - Argenx has announced positive results for the phase II of the phase II/III study (ALKIVIA) evaluating efgartigimod in patients with three sub-types of idiopathic inflammatory myopathies (or myositis). With no quantified press release for the time being, the group has indicated that the study demonstrates a statistically significant therapeutic effect in favour of efgartigimod on the total improvement score (TIS) at week 24 (primary endpoin...
- Hilde Van Boxstael
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Vranken
- Wim Lewi
- Damien Choplain
- Martial Descoutures
Argenx : Efgartigimod passe en phase 3 dans les myosites
>Résultats de phase 2 positifs - Argenx annonce des résultats positifs de la partie phase 2 de la phase 2/3 (ALKIVIA) évaluant efgartigimod chez des patients dans trois sous-types de myopathies inflammatoires idiopathiques (ou myosites). Sans communiqué de résultats chiffrés à ce stade, la société indique que l’étude a démontré un effet thérapeutique en faveur d’efgartigimod statistiquement significatif sur le score total d’amélioration (TIS) à la semaine 24 (critère ...
- Thomas Vranken
argenx Myositis go & model update
argenx announced that it is advancing clinical development of SC efgar in idiopathic inflammatory myopathies (myositis). The ongoing seamless Ph2/3 study is a basket trial across three myositis subsets, IMNM, ASyS and DM, each of which will continue into the Ph3 part. Furthermore, following the strong Q3 update, we have adjusted our model to reflect the sustained strong commercial uptake for Vyvgart in myasthenia gravis (MG), as well as the solid start in CIDP. On the other hand, we have removed...
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic ...
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIAPotential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune dise...
- Thomas Vranken
Onward Medical FIRST LOOK: Grant to assess ARC-BCI in stroke patients
Onward announces a new grant from the EIC for € 6m over 5-years (of which Onward receives almost € 2m) to assess ARC-BCI in stroke patients. The grant underlines the platform potential of Onward's technologies. We continue to look out to FDA approval for Onward's first product ARC-EX, expected by YE24. We reiterate our € 9.1 TP and Buy rating.
- Guy Sips
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Vranken
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.